|
|
||||||||
Ann Thorac Surg 2006;82:1575
© 2006 The Society of Thoracic Surgeons
Anesthesia and Critical Care, Royal Brompton and Harefield NHS Trust, Harefield Hospital, Middlesex UB9 6JH United Kingdom
(Email: d.royston@rbht.nhs.uk).
| The first 20% of the full text of this article appears below. |
To the Editor:
| Dr Royston discloses a financial relationship with Bayer HealthCare, GSK, Organon.
|
I would like to comment on the article by Kincaid and colleagues [1] suggesting an adverse interaction between aprotinin and inhibitors of angiotensin-converting enzyme inhibitor (ACEI).
First, the authors claim a "plausible mechanism" for their observations is induced by vasoconstriction of the efferent glomerular artery. A source reference is not cited. Studies thus far fail to show an effect of aprotinin on angiotensin-stimulated afferent or efferent artery
Related Article
Ann. Thorac. Surg. 2006 82: 1575-1576.
This article has been cited by other articles:
![]() |
E. H. Kincaid, N. D. Kon, and J. W. Hammon Reply. Ann. Thorac. Surg., October 1, 2006; 82(4): 1575 - 1576. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |